- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00873925
Cord Blood Plus Vitamin D and Omega 3s in T1D
Transfusion of Autologous Umbilical Cord Blood Plus Vitamin D and Omega 3 Fatty Acids to Preserve Beta Cell Function in Children With Recent Onset Type 1 Diabetes - A Pilot Study
In this pilot study the investigators are trying to see if a single intravenous infusion of autologous (self) cord blood cells followed by 1 year of daily vitamin D and omega 3 fatty acid supplementation can preserve beta cell function (prolong "honeymoon") in children with type 1 diabetes. All subjects will continue to use insulin therapy as needed to maintain the best possible glucose control.
15 Subjects will be randomized such that 2 of every 3 (10 total) will receive cord blood plus vitamin D and Omega 3 while 1 of 3 (5 total) will serve as controls and will not receive cord blood, vitamin D, or Omega 3 supplementation.
The study will involve 5 visits over 1 year to the University of Florida
This study is a follow-up to our initial study of cord blood infusion alone in which 23 children received autologous cord blood. The initial study was 100% safe but additional studies like the one described above are needed to determine how to improve cord blood based therapy.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Hypothesis: We hypothesize that the combination of intensive insulin therapy, autologous umbilical cord blood (UCB), Vitamin D, and Omega 3 fatty acids administered to children with T1D will preserve residual c-peptide when compared to children receiving intensive insulin therapy alone
Specific Aims:
- Randomize 15 children with recent onset T1D and available autologous cord blood such that 10 receive a combination of intensive insulin therapy, autologous UCB infusion, and daily Vitamin D while 5 receive intensive insulin therapy alone
- Document safety of combination therapy
- Study potential changes in glucose metabolism
- Study potential changes in immune function
Preliminary Studies: Our group has already performed autologous cord blood infusion in 23 children with T1D and has documented the safety of this approach. While conclusive data regarding the efficacy of the infusion in preserving beta cell function are lacking, our pilot study has demonstrated a potential for cord blood to low the rate of c-peptide decline (a measure of beta cell function/mass) in these young children with T1D. As documented above, considerable work both here and other institutions suggests the potential for a combination of Vitamin D and DHA to further augment the autoimmune response. Given the safety and potential efficacy of such an approach, we feel that a pilot study of the combination of UCB infusion, vitamin D supplementation, and DHA supplementation is warranted.
Screening: Only subjects who are still making at least a small amount of detectable insulin will be eligible for this study. To determine if a child is still making insulin, they will undergo a mixed meal tolerance test. This involves placing an IV in the morning prior to eating. The subject then drinks a "mixed meal" (the nutritional supplement Boost is used)and blood is taken via the IV at timepoints over the next 2 hours to determine if insulin is still being produced.
Randomization: If a potential subject "passes" the screening test, they will then be randomized to either receiving the study intervention or to being a control. Subjects WILL be told what arm of the study they are randomized to.
Infusion: Those randomized to infusion will return to the University of Florida for a single autologous cord blood infusion and will be given vitamin D and Omega 3 supplements
Follow-up: Both Control and Intervention subjects will return at 3, 6, and 12 months after the infusion/screening visit to have blood drawn for a repeat mixed meal tolerance test, measurement of HbA1c, and other immune studies.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Florida
-
Gainesville, Florida, Estados Unidos, 32608
- University of Florida
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- TID diagnosis confirmed by presence of at least 1 diabetes autoantibody Children ≥ 1 years
- Stored autologous umbilical cord blood (15 sought) in an AABB and/or FACT accredited cord bank.
- Stimulated C-peptide > 0.2pmol/L on MMTT
- Cord blood meets all selection and testing criteria (see below).
- Normal screening values for CBC, Renal function and electrolytes (BMP with Ca, Mg, and Phos).
- Willing to comply with intensive diabetes management
Exclusion Criteria:
- Complicating medical issues that would interfere with blood drawing or monitoring.
- Chronic use of steroids or other immunosuppressive agents for other conditions.
- Positive infectious disease markers from mother's blood or cord at time of -collection (See below for details).
- Any evidence of illness on planned infusion date (i.e. fever >38.5 C, vomiting, diarrhea, wheezing, or crackles).
- Allergy to DHA (Omega 3) or Vitamin D
- Hypercalcemia
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Autologous UCB Plus Vit D Omega 3 FA
A single autologous (self) intravenous umbilical cord blood infusion followed by 1 year of daily Vitamin D and Omega 3 Fatty Acid supplementation give as liquid drops and gel capsules that can be swallowed or added to food
|
Umbilical Cord Blood stem cells CAN be collected and frozen immediately after birth in private and public cord blood banks.
If a child with recent onset T1D has their OWN cord blood in storage they may qualify for this study.
The cells would be released to the University of Florida where we would perform a single IV infusion of the cells once they have been thawed and washed.
Depending on how the cells are stored, it may be possible to keep some portion of the cells in storage for future use.
Omega 3 Fatty Acids commonly found in fish oil may play an important role in preserving beta cell function via their anti-inflammatory actions.
Those subjects randomized to treatment will take a daily supplement supplied as a capsule that can either be swallowed whole or opened so the contents can be mixed with food.
Vitamin D is important for calcium absorption and bone health but may also play an important role in promoting healthy immune responses.
Subjects randomized to intervention will take vitamin D supplied as a liquid in a dropper (1 drop per day added to food) for 1 year.
|
Sem intervenção: Control
Subjects randomized to be controls will continue to use intensive insulin therapy in order to compare c-peptide production at 1 year in those receiving combination therapy vs those who do not
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
C-Peptide following the 1 year mixed meal tolerance test
Prazo: 1 year post cord blood infusion
|
1 year post cord blood infusion
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
---|---|
DHA Level
Prazo: 1 year post randomization
|
1 year post randomization
|
Vitamin D Level
Prazo: 1 year post randomization
|
1 year post randomization
|
HbA1c and Insulin Dose
Prazo: 1 year post randomization
|
1 year post randomization
|
Peripheral Blood T-cell assays
Prazo: 1 year post randomization
|
1 year post randomization
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Publicações Gerais
- Haller MJ, Viener HL, Wasserfall C, Brusko T, Atkinson MA, Schatz DA. Autologous umbilical cord blood infusion for type 1 diabetes. Exp Hematol. 2008 Jun;36(6):710-5. doi: 10.1016/j.exphem.2008.01.009. Epub 2008 Mar 20.
- Haller MJ, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, Wingard JR, Theriaque DW, Shuster JJ, Ferguson RJ, Kozuch M, Clare-Salzler M, Atkinson MA, Schatz DA. Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes. Biol Blood Marrow Transplant. 2013 Jul;19(7):1126-9. doi: 10.1016/j.bbmt.2013.04.011. Epub 2013 Apr 20.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- UF IRB 696-2008
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Diabetes tipo 1
-
Oxford Brookes UniversityUniversity of OxfordConcluídoAtividade física | Saúde Mental Bem-estar 1 | Função Cognitiva 1, Social | Academic Attainment | Fitness TestingReino Unido
-
SanionaConcluído
-
Calliditas Therapeutics ABEurofins Optimed; York Bioanalytical SolutionConcluído
-
Calliditas Therapeutics ABConcluído
-
National Cancer Institute, NaplesRecrutamentoCâncer de Ovário Recorrente Sensível à Platina BRCA Wild TypeItália
-
Merck Sharp & Dohme LLCRecrutamentoCâncer de Pulmão de Células Não Pequenas | Tumores Sólidos | Morte Celular Programada-1 (PD1, PD-1) | Ligante 1 de morte celular programada 1 (PDL1, PD-L1) | Ligante 2 de morte celular programada 1 (PDL2, PD-L2)Japão
-
Rambam Health Care CampusIsrael Science FoundationConcluído
-
Alvotech Swiss AGConcluído
-
PfizerConcluído
-
Reproductive Medicine Associates of New JerseyConcluídoCada paciente é tanto caso quanto controle | 1 embrião será biopsiado e 1 embrião não seráEstados Unidos
Ensaios clínicos em Autologous UCB
-
Davidzon, Guido, M.D.Stanford UniversitySuspenso
-
University of Wisconsin, MadisonNational Institute on Aging (NIA)Ativo, não recrutando
-
Celgene CorporationDesconhecidoMalignidades hematológicasEstados Unidos
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Recrutamento
-
Sheba Medical CenterRecrutamentoLesões cerebrais | Doença Cardíaca Congênita | Distúrbio Neonatal | Síndrome de Baixo Débito CardíacoIsrael
-
Alkermes, Inc.University Medical Center Groningen; Amsterdam UMC, location VUmc; QPS Netherlands...ConcluídoSaudável | Doença de AlzheimerHolanda
-
UCB PharmaRetirado
-
Yale UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Ainda não está recrutandoMal de Parkinson | Transtorno Depressivo Maior
-
Yale UniversityNational Center for Complementary and Integrative Health (NCCIH)RecrutamentoComportamento, SaúdeEstados Unidos